This segment focuses on the research, development, and commercialization of therapies for Transthyretin Amyloidosis (ATTR), a rare and progressive disease caused by the misfolding and aggregation of the transthyretin (TTR) protein. Eidos Therapeutics' primary focus was on developing acoramidis (formerly AG10), a novel oral TTR stabilizer designed to address both hereditary and wild-type ATTR cardiomyopathy (ATTR-CM). Research and development activities included preclinical studies, clinical trials (Phase 1, Phase 2, and Phase 3), and formulation optimization. The goal was to improve patient outcomes by preventing TTR misfolding and reducing amyloid deposition in the heart and other organs. This segment aimed to provide a convenient and effective treatment option for ATTR patients, potentially slowing disease progression and improving quality of life. The competitive advantage lies in the oral administration and potential for near-complete TTR stabilization.